Acasti Pharma Inc expected to post a loss of 47 cents a share - Earnings Preview

Grace Therapeutics

19/06/2024 13:33

* Acasti Pharma Inc  ACST.OQ   ACST.O  is expected to show
no
change in quarterly revenue when it reports  results on June 21
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Acasti Pharma Inc is for
a
loss of 47 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acasti
Pharma Inc
is $6.00​, above​ its last closing price of $3.29. ​​​

This summary was machine generated June 19 at 12:33 GMT.  All
figures in Canadian dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)